AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21924093 — intervention group
Group type: COMPARATOR
Intervention: Partial inferior turbinectomy and/or septal-plasty (group B)
Number of subjects: 191
Study 21924093 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 191
Study 19090588 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 16
Study 19090588 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 17881181 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol
Number of subjects: 0
Study 17881181 — intervention group
Group type: EXPERIMENTAL
Intervention: Melitracen
Number of subjects: 0
Study 15302727 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil (1.25 ng/kg/min, titrated to a maximum of 22.5 ng/kg/min)
Number of subjects: 90
Study 15302727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15848533 — intervention group
Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal protocol using basiliximab, CsA (8 mg/kg), MMF (2000 mg), and methylprednisolone (500 mg) rapidly tapered and withdrawn at 14 POD
Number of subjects: 118
Study 15848533 — intervention group
Group type: COMPARATOR
Intervention: Triple regimen consisting of CsA (same dose), MMF (same dose), and methylprednisolone (250 mg) tapered and continued
Number of subjects: 118
Study 15848533 — intervention group
Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal protocol using basiliximab
Number of subjects: 118
Study 15848533 — intervention group
Group type: COMPARATOR
Intervention: Triple regimen consisting of CsA, MMF, and methylprednisolone
Number of subjects: 118
Study 11042565 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m² on Days 1, 8, and 15 plus cisplatin 80 mg/m² on Day 2 (arm A)
Number of subjects: 82
Study 9493664 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive out-patient rehabilitation programme (physical training, occupational therapy, education, smoking cessation therapy) for 12 weeks
Number of subjects: 47
Study 9493664 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive out-patient rehabilitation programme
Number of subjects: 47
Study 9493664 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control intervention was)
Number of subjects: 47
Study 8113483 — intervention group
Group type: EXPERIMENTAL
Intervention: Social relations intervention
Number of subjects: 52
Study 8113483 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 52
Study 3553220 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (4 micrograms/kg X min; 1 h)
Number of subjects: 0
Study 3553220 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (2 ng/kg X min; 2 h)
Number of subjects: 0
Study 3553220 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.15 M saline, 5 h)
Number of subjects: 0
Study 3553220 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (2 ng/kg X min; 2 h) plus dopamine (4 micrograms/kg X min; 1 h)
Number of subjects: 0
Study 3553220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg/dose)
Number of subjects: 0
Study 3553220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2502583 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of rIFN‐gamma
Number of subjects: 16
Study 2502583 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of rIFN‐gamma
Number of subjects: 16
Study 2502583 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of rIFN‐gamma
Number of subjects: 16
Study 2502583 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of rIFN‐gamma
Number of subjects: 16
Study 31060619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) plus usual care
Number of subjects: 60
Study 31060619 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 28402480 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental stress induction
Number of subjects: 120
Study 28402480 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study 26369412 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Anxiety
Number of subjects: 204
Study 26369412 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Depression
Number of subjects: 204
Study 26369412 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Pain Interference
Number of subjects: 204
Study 26369412 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Physical Function
Number of subjects: 204
Study 23240637 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer (BC)
Number of subjects: 1440
Study 23240637 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer characteristics and treatment
Number of subjects: 1440
Study 23240637 — intervention group
Group type: COMPARATOR
Intervention: Breast cancer-free women
Number of subjects: 1440
Study 21284660 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical slimming cream
Number of subjects: 0
Study 21284660 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 0
Study 19631292 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 (3.6 x 10(12) CFU, twice daily for 12 weeks)
Number of subjects: 147
Study 19631292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 17549330 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 208
Study 17549330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 17549330 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient (Coeff) in Norsk Grunntest for Afasi
Number of subjects: 208
Study 17549330 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsterdam‐Nijmegen Everyday Language Test (ANELT)
Number of subjects: 208
Study 17549330 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient (Coeff)
Number of subjects: 208
Study 15045624 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (THA) 20 mg (1 ml)
Number of subjects: 57
Study 15045624 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MPA) 40 mg (1 ml)
Number of subjects: 57
Study 11124794 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ethinyloestradiol 50‐75 ng/kg/day, GH 28 IU/m(2) surface area/week as a daily injection
Number of subjects: 58
Study 11124794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ethinyloestradiol and GH
Number of subjects: 58
Study 11124794 — intervention group
Group type: COMPARATOR
Intervention: Low dosage ethinyloestradiol
Number of subjects: 58
Study 11124794 — intervention group
Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 58
Study 10898562 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention promoting fruit and vegetable consumption (classroom, parent, and environmental components)
Number of subjects: 1698
Study 10898562 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specific details provided)
Number of subjects: 1698
Study 7857363 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg/day GEM
Number of subjects: 18
Study 7857363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2509590 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT (aztreonam/amikacin/ticarcillin)
Number of subjects: 45
Study 2509590 — intervention group
Group type: COMPARATOR
Intervention: LAT (latamoxef/amikacin/ticarcillin)
Number of subjects: 45
Study 1098359 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil + Levodopa
Number of subjects: 15
Study 1098359 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil + Amantadine
Number of subjects: 15
Study 1098359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31468636 — intervention group
Group type: EXPERIMENTAL
Intervention: NAR150 (150 mg)
Number of subjects: 18
Study 31468636 — intervention group
Group type: EXPERIMENTAL
Intervention: NAR600 (600 mg)
Number of subjects: 18
Study 31468636 — intervention group
Group type: EXPERIMENTAL
Intervention: NAR300 (300 mg)
Number of subjects: 18
Study 31468636 — intervention group
Group type: EXPERIMENTAL
Intervention: NAR900 (900 mg)
Number of subjects: 18
Study 31468636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31044290 — intervention group
Group type: EXPERIMENTAL
Intervention: THC-dominant cannabis (125 mg, 11% THC; < 1% CBD)
Number of subjects: 14
Study 31044290 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD equivalent cannabis (125 mg, 11% THC, 11% CBD)
Number of subjects: 14
Study 31044290 — intervention group
Group type: COMPARATOR
Intervention: Placebo (< 1% THC/CBD)
Number of subjects: 14
Study 28727817 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose DgDgM_M
Number of subjects: 48
Study 28727817 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose DgDgMM_M
Number of subjects: 48
Study 28727817 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd dose of MVA
Number of subjects: 48
Study 28727817 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-expressed GM-CSF
Number of subjects: 48
Study 25437881 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin calcium, 20mg daily
Number of subjects: 17802
Study 25437881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study 25437881 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hs-CRP levels
Number of subjects: 17802
Study 23770109 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ)
Number of subjects: 260
Study 23770109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 21305544 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness strategy for managing cravings
Number of subjects: 61
Study 21305544 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression strategy for managing cravings
Number of subjects: 61
Study 19356881 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Activation Measure (PAM)
Number of subjects: 625
Study 19356881 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM
Number of subjects: 625
Study 17316364 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonplatinum therapy
Number of subjects: 161
Study 17316364 — intervention group
Group type: COMPARATOR
Intervention: Platinum combination therapy
Number of subjects: 161
Study 15016018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation
Number of subjects: 25
Study 15016018 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand curettes
Number of subjects: 25
Study 15016018 — intervention group
Group type: COMPARATOR
Intervention: Control untreated surfaces
Number of subjects: 25
Study 11748394 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with clonidine (10 microg/ml)
Number of subjects: 7
Study 11748394 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine (1%)
Number of subjects: 7
Study 9580757 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified consent procedure (opting out)
Number of subjects: 44
Study 9580757 — intervention group
Group type: COMPARATOR
Intervention: Conventional consent procedure (opting in)
Number of subjects: 44
Study 8049313 — intervention group
Group type: EXPERIMENTAL
Intervention: tegafur 600 mg orally daily for two years
Number of subjects: 243
Study 8049313 — intervention group
Group type: EXPERIMENTAL
Intervention: tegafur‐uracil 600 mg orally daily for two years
Number of subjects: 243
Study 8049313 — intervention group
Group type: EXPERIMENTAL
Intervention: mitomycin C 20 mg intravenous bolus on the day of operation and 10 mg on the first postoperative day, plus mitomycin C 10 mg every three months for stage IV patients
Number of subjects: 243
Study 8049313 — intervention group
Group type: EXPERIMENTAL
Intervention: histological curative resections
Number of subjects: 243
Study 3133211 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (5-15 mg)
Number of subjects: 18
Study 3133211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30734104 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 s MVC
Number of subjects: 120
Study 30734104 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-15 s MVC and 6×5-MVC protocols
Number of subjects: 120
Study 30734104 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-30 s repetitive MVC modalities and 15 electrical stimuli
Number of subjects: 120
Study 27987231 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-entacapone-carbidopa intestinal gel after a 20% dose reduction
Number of subjects: 11
Study 27987231 — intervention group
Group type: COMPARATOR
Intervention: Levodopa-carbidopa intestinal gel (usual dose)
Number of subjects: 11
Study 26595801 — intervention group
Group type: EXPERIMENTAL
Intervention: PPROM with latency ≥4 weeks
Number of subjects: 1522
Study 26595801 — intervention group
Group type: COMPARATOR
Intervention: PPROM with latency <4 weeks
Number of subjects: 1522
Study 25812762 — intervention group
Group type: EXPERIMENTAL
Intervention: Best endovascular therapy
Number of subjects: 0
Study 25812762 — intervention group
Group type: COMPARATOR
Intervention: Best open surgical treatment
Number of subjects: 0
Study 23101952 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 20
Study 23101952 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 20
Study 19777109 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-panel platform
Number of subjects: 0
Study 19777109 — intervention group
Group type: COMPARATOR
Intervention: Traditional video platform
Number of subjects: 0
Study 19777109 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous 2 examinations performance
Number of subjects: 0
Study 19777109 — intervention group
Group type: EXPERIMENTAL
Intervention: PCAT scores
Number of subjects: 0
Study 17688757 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain in the last 4 weeks
Number of subjects: 1090
Study 17688757 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain experience in the 'oldest old'
Number of subjects: 1090
Study 17688757 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis as a factor in pain reporting
Number of subjects: 1090
Study 17688757 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of pain on activities of daily living
Number of subjects: 1090
Study 17688757 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported health status among those with pain
Number of subjects: 1090
Study 17688757 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between pain and depressed mood
Number of subjects: 1090
Study 15465740 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA-enriched diet (38% fat, 20% SFA)
Number of subjects: 84
Study 15465740 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-rich diet (30% fat, < 10% SFA, 55% carbohydrate)
Number of subjects: 84
Study 15465740 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA olive oil-rich diet (38% fat, 22% MUFA)
Number of subjects: 84
Study 11802939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae vaccine (M. vaccae vaccine) with chemotherapy regimen of 2HRZE/2HR for 6 months
Number of subjects: 342
Study 11802939 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy regimen of 2HRZE/4HR
Number of subjects: 342
Study 9671334 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study 9671334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7809517 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral balloon valvuloplasty (PMV)
Number of subjects: 80
Study 7809517 — intervention group
Group type: COMPARATOR
Intervention: Mitral commissurotomy (MC)
Number of subjects: 80
Study 2972790 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 248
Study 2972790 — intervention group
Group type: COMPARATOR
Intervention: Graduated compression stockings (TED stockings)
Number of subjects: 248
Study 2972790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both subcutaneous heparin and stockings
Number of subjects: 248
Study 30406406 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial (AM) technique
Number of subjects: 20
Study 30406406 — intervention group
Group type: COMPARATOR
Intervention: Transtibial (TT) technique
Number of subjects: 20
Study 27535481 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral micronized progesterone
Number of subjects: 12
Study 27535481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24894509 — intervention group
Group type: EXPERIMENTAL
Intervention: Expansion Plate
Number of subjects: 30
Study 24894509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax Expander
Number of subjects: 30
Study 24894509 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 30
Study 23841973 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 40
Study 23841973 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study 20667937 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin (1500 mg/day over 8 weeks, maintained for 12 weeks)
Number of subjects: 15
Study 20667937 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 15
Study 18687278 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment options for osteoarthritis, specific interventions not detailed.
Number of subjects: 0
Study 18687278 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical approach to management of OA, specific medications not detailed.
Number of subjects: 0
Study 16192520 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol emulsion containing medium-chain triglyceride
Number of subjects: 130
Study 16192520 — intervention group
Group type: COMPARATOR
Intervention: Lipid-free propofol
Number of subjects: 130
Study 12897033 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 microm albuterol aerosol at 20 microg
Number of subjects: 18
Study 12897033 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 microm albuterol aerosol at 20 microg
Number of subjects: 18
Study 12897033 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 microm albuterol aerosol
Number of subjects: 18
Study 12897033 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 18
Study 12897033 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 microm and 3 microm aerosols
Number of subjects: 18
Study 10821987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nalmefene 50 mg
Number of subjects: 7
Study 10821987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nalmefene 100 mg
Number of subjects: 7
Study 10821987 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 10 mg
Number of subjects: 7
Study 10821987 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 20 mg
Number of subjects: 7
Study 10821987 — intervention group
Group type: COMPARATOR
Intervention: Oral nalmefene 0 mg (placebo)
Number of subjects: 7
Study 8644834 — intervention group
Group type: EXPERIMENTAL
Intervention: Kendall-Futuro #33 (Futuro)
Number of subjects: 23
Study 8644834 — intervention group
Group type: EXPERIMENTAL
Intervention: AliMed Freedom Short (AliMed Short)
Number of subjects: 23
Study 8644834 — intervention group
Group type: EXPERIMENTAL
Intervention: Smith & Nephew Rolyan D‐Ring (Rolyan)
Number of subjects: 23
Study 8644834 — intervention group
Group type: EXPERIMENTAL
Intervention: LMB Wrist Rest (LMB)
Number of subjects: 23
Study 8644834 — intervention group
Group type: EXPERIMENTAL
Intervention: AliMed Freedom Long (AliMed Long)
Number of subjects: 23
Study 8644834 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolyan D‐Ring (Rolyan)
Number of subjects: 23
Study 8444696 — intervention group
Group type: COMPARATOR
Intervention: Acute acetazolamide (500 mg iv)
Number of subjects: 5
Study 8444696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic acetazolamide (500 mg po every 6 h)
Number of subjects: 5
Study 8444696 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 5
Study 3079687 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% fat emulsion
Number of subjects: 16
Study 3079687 — intervention group
Group type: COMPARATOR
Intervention: 10% fat emulsion
Number of subjects: 16
Study 30902738 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (2 g per day of eicosapentaenoic acid (EPA) and 1 g of DHA)
Number of subjects: 59
Study 30902738 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 59
Study 30902738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 30138433 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care program for late-life depression
Number of subjects: 119
Study 30138433 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119
Study 24359500 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK239512 (10-20-40-80 µg)
Number of subjects: 196
Study 24359500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 22077482 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oral phytoestrogen (Promensil)/day
Number of subjects: 43
Study 22077482 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg oral phytoestrogen (Promensil)/day
Number of subjects: 43
Study 22077482 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mg transdermal oestrogen/day
Number of subjects: 43
Study 22077482 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg transdermal oestrogen/day
Number of subjects: 43
Study 20427397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 136
Study 20427397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 20427397 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 expression
Number of subjects: 136
Study 18020844 — intervention group
Group type: EXPERIMENTAL
Intervention: Human advice
Number of subjects: 218
Study 18020844 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated advice
Number of subjects: 218
Study 18020844 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 218
Study 16258776 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 62